Roivant Sciences Ltd.
Roivant Sciences Ltd. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q2 FY26 call signalled
1 of 1 strong
The short version
- Roivant expects significant growth driven by multiple programs, particularly brepocitinib, with close to 300,000 addressable patients across existing indications. - Roivant expects a transformative year ahead with multiple upcoming data readouts, including brepocitinib's Phase III study in cutaneous sarcoidosis and NIU Phase III top line data.
From Roivant Sciences Ltd.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Roivant expects significant growth driven by multiple programs, particularly brepocitinib, with close to 300,000 addressable patients across existing indications.
- Commercial preparation for the dermatomyositis (DM) launch is underway, targeted for end of September, potentially boosting sales.
- Enrollment and execution across key clinical programs like 1402 and Graves’ disease are strong, supporting future product approvals and market launches.
- Expansion into new indications such as Lichen Planopilaris (LPP) for brepocitinib presents additional revenue opportunities.
- Continued presentations and publications, including Phase III data in NEJM, enhance market visibility.
2 more points from Roivant Sciences Ltd.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Roivant Sciences Ltd. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The call does not explicitly detail current or future capital expenditures (capex) or strategic investments.
- However, it mentions active commercial preparation activities, such as:
- Launch preparations for brepocitinib in dermatomyositis planned by the end of September.
- Initiation of a Phase III study in cutaneous sarcoidosis within the year.
- Enrollment ongoing in clinical trials including LPP indication for brepocitinib and Phase IIb data expected for another program in second half of the year.
- The company discusses significant R&D investments with increased spending given program scope expansion.
2 more points from Roivant Sciences Ltd.'s call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Roivant Sciences Ltd. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Continue your research
Others in Biotechnology this season
- Arrowhead Pharmaceuticals, Inc. (Q2 FY26)
Arrowhead Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. REDEMPLO launch momentum continues strong with prescriptions accelerating nearly threefold o
- Madrigal Pharmaceuticals, Inc. (Q2 FY26)
Madrigal Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. The company expects steady patient additions and robust net sales growth through 2026, with Q
- Exelixis, Inc. (Q2 FY26)
Exelixis, Inc. Q2 FY26 quarterly results analysis. CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. Market Cap $12,932, P/E 16.5. AI-powered ea
- Ionis Pharmaceuticals, Inc. (Q2 FY26)
Ionis Pharmaceuticals, Inc. Q2 FY26 quarterly results analysis. DAWNZERA sales expected at $110M-$120M in 2026, driven by switches from existing prophylactics a
Arthneeti Pro · Annual
Roivant Sciences Ltd. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Roivant Sciences Ltd. Q2 FY26 results?
- Roivant expects significant growth driven by multiple programs, particularly brepocitinib, with close to 300,000 addressable patients across existing indications. - Roivant expects a transformative year ahead with multiple upcoming data readouts, including brepocitinib's Phase III study in cutaneous sarcoidosis and NIU Phase III top line data.
What is Roivant Sciences Ltd. share price analysis?
Roivant Sciences Ltd. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of -19.0 with a market cap of $21,492. Investors should review the full earnings analysis for detailed insights.
Is Roivant Sciences Ltd. planning capital expenditure?
- The call does not explicitly detail current or future capital expenditures (capex) or strategic investments.
Keep Roivant Sciences Ltd. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.